August 18, 2005 13:30 ET

Second-Hand Smoke Costs $10 Billion A Year According to Insurance Study; Nymox TobacAlert™ Product Detects Second-Hand Smoke Exposure

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Aug 18, 2005) -

A recent study commissioned by the Society of Actuaries found that second-hand smoke exposure costs the U.S. economy approximately $10 billion a year: $5 billion for direct medical costs and $5 billion for indirect costs from lost wages, reduced services and disabilities. The researchers led by Dr. Donald Behan of Georgia State University tallied up the estimated costs associated with the increased risk of lung cancer, asthma, chronic pulmonary diseases, coronary artery diseases and other conditions associated with second-hand smoke exposure. The researchers estimated that second-hand smoke exposure causes approximately 40,000 additional deaths per year in the U.S. alone. The report did not attempt to quantify the direct medical costs associated with the known effects of second-hand smoke exposure on pregnancies and newborns.

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX